Shares of Nantkwest Inc (NASDAQ:NK) traded down 7.3% during mid-day trading on Tuesday . The stock traded as low as $1.41 and last traded at $1.40, 4,391 shares were traded during mid-day trading. A decline of 98% from the average session volume of 177,252 shares. The stock had previously closed at $1.51.
Separately, ValuEngine cut shares of Nantkwest from a “buy” rating to a “hold” rating in a research note on Friday.
The company has a quick ratio of 5.72, a current ratio of 5.72 and a debt-to-equity ratio of 0.09. The business’s fifty day moving average price is $1.22 and its 200 day moving average price is $1.19. The firm has a market capitalization of $169.19 million, a PE ratio of -1.15 and a beta of 2.52.
Nantkwest (NASDAQ:NK) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.02. Nantkwest had a negative net margin of 164,604.89% and a negative return on equity of 44.91%. The company had revenue of $0.01 million during the quarter.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC bought a new stake in shares of Nantkwest in the second quarter valued at about $37,000. Morgan Stanley increased its holdings in Nantkwest by 303.8% during the second quarter. Morgan Stanley now owns 48,497 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 36,486 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Nantkwest by 4,218.8% in the third quarter. Tower Research Capital LLC TRC now owns 47,766 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 46,660 shares during the period. Jane Street Group LLC bought a new position in Nantkwest in the second quarter worth approximately $92,000. Finally, Paloma Partners Management Co bought a new position in Nantkwest in the second quarter worth approximately $127,000. Institutional investors and hedge funds own 5.50% of the company’s stock.
About Nantkwest (NASDAQ:NK)
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Featured Story: What is channel trading?
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.